Network meta-analysis for deaths_(OS)

Network meta-analysis estimations pool direct and indirect evidences. These results should be considered as exploratory given the absence of assessment of transitivity assumption plausibility. Calculations by netmeta package.

Evidence network for deaths_(OS)

1CONDOR (DT vs D ; PDL1 TC<25%), 20191CONDOR (DT vs T ; PDL1 TC<25%), 2019durvalumab alone vs. durvalumab plus tremelimumab 1.01 [0.70; 1.45]1.01 [0.70;1.45]durvalumab alone vs. durvalumab plus tremelimumab 1.01 [0.70; 1.45]durvalumab alone vs. tremelimumab 0.73 [0.44; 1.21]0.73 [0.44;1.21]durvalumab alone vs. tremelimumab 0.73 [0.44; 1.21]durvalumab plus tremelimumab vs. durvalumab alone 0.99 [0.69; 1.43]0.99 [0.69;1.43]durvalumab plus tremelimumab vs. durvalumab alone 0.99 [0.69; 1.43]durvalumab plus tremelimumab vs. tremelimumab 0.72 [0.51; 1.02]0.72 [0.51;1.02]durvalumab plus tremelimumab vs. tremelimumab 0.72 [0.51; 1.02]tremelimumab vs. durvalumab alone 1.37 [0.83; 2.28]1.37 [0.83;2.28]tremelimumab vs. durvalumab alone 1.37 [0.83; 2.28]tremelimumab vs. durvalumab plus tremelimumab 1.39 [0.98; 1.97]1.39 [0.98;1.97]tremelimumab vs. durvalumab plus tremelimumab 1.39 [0.98; 1.97]durvalumab alonetremelimumabdurvalumab plus tremelimumabdirect evidencenetwork meta-analysis
T vs. C durvalumab alonetremelimumabdurvalumab plus tremelimumab
durvalumab alone---0.73
0.44; 1.21		1.01
0.70; 1.45
tremelimumab1.37
0.83; 2.28		---1.39
0.98; 1.97
durvalumab plus tremelimumab0.99
0.69; 1.43		0.72
0.51; 1.02		---

pathologies: 192 - treatments: 634,861 result logic

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons